Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiologyheart failure, electrophysiologyhypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

24% of heart failure patients hospitalized with COVID-19 die

The authors examined data from more than 1.2 million patients, tracking individuals who had previously been hospitalized for heart failure and then returned later due to COVID-19. 

Thumbnail

TAVR in the time of COVID-19: Providers quickly adapted, delivering ‘excellent’ outcomes

Researchers compared patient outcomes from 2019 with data from the pandemic’s first four months, sharing their findings in the American Journal of Cardiology.  

Thumbnail

What new research tells us about stroke mortality among men and women

Prior to popular belief, sex may not necessarily be an independent risk factor for stroke mortality, according to the analysis. 

Thumbnail

No reason to quit: TAVR patients can continue anticoagulation therapy throughout procedure

Patients are typically told to put anticoagulation therapy on hold two to four days before they undergo TAVR. This study’s authors aimed to see if this was truly necessary.  

COVID-19 hospitalizing more children, raising new worries about resources

The national average increase over the study period was 760%—from 2.0 pediatric hospitalizations per 100,000 persons in May to 17.2 in November.

When hospitalized COVID-19 patients head home, the cardiovascular challenges continue

The research included data from more than 47,000 hospitalized COVID-19 patients. 

Frontline healthcare workers maintaining mental resilience during COVID crisis

Researchers have found nonmedical working professionals bearing significantly more depression and anxiety these days than doctors and nurses working with or near COVID-19 patients.

Thumbnail

Empagliflozin provides additional benefits to patients with type 2 diabetes and CAD

The authors found a link between six months of empagliflozin and a reduction in extracellular volume, sharing their findings in JACC: Cardiovascular Imaging.